This study focuses on people with moderate to severe Crohn’s Disease, a condition that causes inflammation in the digestive system. The study will test a new medication called AZD7798, which is given as an injection under the skin. Some participants will receive the actual medication, while others will receive a placebo.
The purpose of this study is to determine how effective and safe AZD7798 is in treating Crohn’s Disease. The medication will be provided as a freeze-dried powder that is mixed into a solution before injection. The study will look at how well the treatment works in reducing disease symptoms and improving the condition of the intestines.
During the study, participants will receive subcutaneous (under the skin) injections of either AZD7798 or placebo for up to 48 weeks. The study will monitor various aspects of the disease, including symptoms such as abdominal pain and stool frequency, as well as examining the healing of the intestinal lining. Blood samples will be taken to measure the amount of medication in the body and to check for the development of antibodies against the study drug.
Austria 
Belgium 
Bulgaria 
Croatia 
France 
Germany 
Hungary 
Italy 
Poland 
Romania 
Slovakia 
Spain 
Sweden 
The Netherlands 
